Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | A-1210477 + Lapatinib + WEHI-539 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
A-1210477 | AOB5551 | MCL1 Inhibitor 18 | A-1210477 binds to and inhibits MCL1, resulting in increased apoptosis of MCL1-dependent tumor cells (PMID: 25590800, PMID: 30647404, PMID: 32486166). | |
Lapatinib | Tykerb | Lapatinib Ditosylate | EGFR Inhibitor (Pan) 62 HER2 Inhibitor 42 | Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive (overexpressing) breast cancer (FDA.gov). |
WEHI-539 | BCL-XL inhibitor 14 | WEHI-539 is a selective inhibitor of BCL-XL that stimulates apoptotic responses in cells, resulting in killing of tumor cells (PMID: 23603658, PMID: 32752193). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|